Activist investor Trian Fund Management plans to push Solventum to separate more of its businesses after the company’s $4.1 ...

Thermo Fisher’s release goes on to suggest that it believes it can more than double the profitability of Purification & Filtration under its corporate umbrella, relative to the business’ current ...

Trian Fund Management, which beneficially owns about 5% of Solventum (SOLV) and is the company’s largest active shareholder, commented on ...

M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.

Contract drug manufacturer Thermo Fisher Scientific said on Tuesday it will buy Solventum's purification and filtration ...

Investing.com -- Activist investor Trian Fund Management is reportedly planning to urge Solventum to separate additional businesses following the company’s $4.1 billion deal to sell its filtration ...

Solventum faces significant challenges in its turnaround, including slow-growing core businesses, share loss, and margin ...

L.P. (“Trian”), which beneficially owns ~5% of Solventum Corporation (NYSE: SOLV) (“Solventum” or the “Company”) and is the Company’s largest active shareholder, commented on ...

Nelson Peltz’s firm has held a roughly 5% stake in Solventum since the middle of last year. Solventum, which sells healthcare products, was spun out from 3M in April 2024.

“Trian commends Solventum on the announced sale of its Purification & Filtration business and believes this is an important first step in the Company’s value creation journey. We believe that part of ...